Cancer Gene Therapy

Global Market Trajectory & Analytics

MCP10864

EXECUTIVE ENGAGEMENTS

POOL

1928
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

347
Interactions with Platform & by Email

PARTICIPANTS

77
Unique # Participated

VALIDATIONS

17
Responses Validated*

COMPANIES

42
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2022

TABLES

123

PAGES

194

EDITION

5

PRICE

USD 4950

CODE

MCP10864


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

S M N T

%

VALIDATED RESEARCH *

S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T

* S = Strong; M = Moderate; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
  

HIGHLIGHTS & REPORT INDEX

Global Cancer Gene Therapy Market to Reach $2.9 Billion by 2026

Amid the COVID-19 crisis, the global market for Cancer Gene Therapy estimated at US$611.9 Million in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2026, growing at a CAGR of 29.6% over the analysis period. Oncolytic Virotherapy, one of the segments analyzed in the report, is projected to record a 30.3% CAGR and reach US$1.8 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gene Transfer Therapy segment is readjusted to a revised 28.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $248.7 Million in 2021, While China is Forecast to Reach $508.5 Million by 2026

The Cancer Gene Therapy market in the U.S. is estimated at US$248.7 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$508.5 Million by the year 2026 trailing a CAGR of 28.7% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.7% and 25.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 20.7% CAGR.

Gene-Induced Immunotherapy Segment to Reach US$561.3 Million by the year 2026

In the global Gene-Induced Immunotherapy segment, USA, Canada, Japan, China and Europe will drive the 30.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.5 Million in the year 2020 will reach a projected size of US$575.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

SELECT PLAYERS

Adaptimmune Therapeutics plc; Advantagene, Inc.; Altor Bioscience (a NANT Company); Anchiano Therapeutics, Inc.; bluebird bio, Inc.; Genelux Corporation; GlaxoSmithKline PLC; Merck & Co., Inc.; OncoGenex Pharmaceuticals, Inc.; Shanghai Sunway Biotech Co., Ltd.; Shenzhen SiBiono GeneTech Co., Ltd.; ZIOPHARM Oncology, Inc.

SEGMENTS

» Segment (Oncolytic Virotherapy, Gene Transfer Therapy, Gene-Induced Immunotherapy)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oncolytic Virotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Gene Transfer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Gene-Induced Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com